Atara partners with Merck to conduct a Phase I/II trial evaluating Atara's ATA129 in combination with Merck's Keytruda to treat nasopharyngeal carcinoma (NPC)

Atara Biotherapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$478.3m on 04/21/2017 [market cap]

Research Partner

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Merck & Co. Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Research Partner

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced